By Shiksha Mantri, Ph.D., and Adela Kasselkus, Ph.D., Millipore Sigma
Lipid-based formulations have shown significant promise in drug development and delivery. In addition to enhancing the stability of the API in vivo,1 they boost the bioavailability of both hydrophilic and hydrophobic drugs. Lipid-based formulations also improve the toxicity profile of the entrapped API via passively targeting inflamed or tumor tissues or certain organs1 and enable the delivery of difficult APIs, such as RNA, that are prone to instability, nuclease-mediated lysis, strong immune responses, and an inability to reach the site of action. They also facilitate patient compliance by reducing dosing frequency and/or increasing tolerability.
These benefits can be realized for patients with a wide range of disease indications. In addition, lipid-based drug-delivery systems (LBBDSs) can be used to formulate drugs in the most common dosage forms, including topical, oral, pulmonary, or parenteral administration.
Learn how working with the right supplier that offers consistent, high-quality products and has expertise in the drug development process and the regulatory environment is essential for the successful development and commercialization of lipid-based drug products.